Press Release | January 6, 2023
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
Read More
Press Release | January 5, 2023
Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases
Read More
Press Release | January 5, 2023
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Read More
Press Release | January 5, 2023
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
Read More
